News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


Antiangiogenic treatments prolong OS in glioblastoma subgroup

Al's Comment:

 This is exciting.  They found that  Avastin can more than double the survival for patients who have highly vascularized tumors.  The test they use - perfusion MRI is readily available.  This shows how antiquated our clinical trial system is.  It is going to be very hard to find a single treatment that cures everyone.  Until we find that, we have to use what we have.  That is many treatments that each help a small group  tremendously, helps a little in a larger group, and not at all in others.  Avastin failed when they did a trial mixing all patients.  The best way to have run the trial is to test early to see how the treatment is doing, and figure out which subgroups benefit and which do not. At that point, they should stop accruing patients that they know will not do well - let them try other trials.  But we are not doing that now. (There is some work going on to try this - called adaptive trial design - but it is not widespread).   Obviously, the best way is to get as many of these treatments approved so we can use them in rational combinations. Figure out which treatments will help YOUR particular tumor, and combine the few that look best. 

Posted on: 01/25/2017

Antiangiogenic treatments prolong OS in glioblastoma subgroup


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557